MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Proceeds from exercise ofoptions$2,332K (291.93%↑ Y/Y)Net cash provided byfinancing activities$2,332K (291.93%↑ Y/Y)Net decrease in cashand cash...-$226,863K (-327.20%↓ Y/Y)Canceled cashflow$2,332K Proceeds from maturitiesand sales of...$60,000K Stock-based compensation$8,238K (18.65%↑ Y/Y)Accounts payable andaccrued...$4,961K (282.73%↑ Y/Y)Non-cash lease expense$277K (-20.63%↓ Y/Y)Net amortization ofpremiums and discounts on...-$237K Depreciation$44K (15.79%↑ Y/Y)Net cash used ininvesting activities-$184,989K Net cash used inoperating activities-$44,206K (17.68%↑ Y/Y)Canceled cashflow$60,000K Canceled cashflow$13,757K Purchase of marketablesecurities$244,929K Net loss-$55,436K (13.70%↑ Y/Y)Purchase of property andequipment$60K Prepaid expenses andother assets$1,400K (129.52%↑ Y/Y)Accounts payable andaccrued...-$850K (-156.70%↓ Y/Y)Operating leaseliabilities-$277K (14.24%↑ Y/Y)
Cash Flow

Bicara Therapeutics Inc. (BCAX)

Bicara Therapeutics Inc. (BCAX)

source: myfinsight.com